FDA Grants Accelerated Approval to Zanidatamab-hrii for Patients with Previously Treated Unresectable or Metastatic HER2-positive Biliary Tract Cancer By Ogkologos - December 17, 2024 234 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the HERIZON-BTC-01 study Source RELATED ARTICLESMORE FROM AUTHOR Patient Guide on Cancer Pain Management Now Available Also in French FDA Approves Pembrolizumab with Enfortumab Vedotin-ejfv for Muscle Invasive Bladder Cancer Postneoadjuvant Trastuzumab Deruxtecan Results in Higher Likelihood of iDFS Among Patients with HER2-positive EBC with Residual Invasive Disease After Neoadjuvant Treatment MOST POPULAR ASCO20 Virtual Research Round Up Podcast: Head and Neck Cancer and... August 13, 2020 Cancer Research UK report highlights stark cancer inequalities across Scotland November 28, 2022 Accepting Help During Cancer Is Hard, But It Can Benefit You... January 19, 2023 2023 ASCO Annual Meeting Research Round Up: New Research in Treating... September 28, 2023 Load more HOT NEWS Most Cases of Venous Thromboembolic Events, Elevated Aminotransferases, and Interstitial Lung... UK health inequalities: 20,000 more cancer cases a year in the... Death Rates from Ovarian Cancer will Fall in the EU and... Percentage of Cancer Patients Who Are Eligible for and Respond to...
